Production (Stage)
Neuphoria Therapeutics Inc.
NEUP
$6.87
-$0.28-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 679.54% | -141.46% | 69.27% | 5.72% | 39.00% |
| Total Depreciation and Amortization | -0.42% | 0.24% | -50.02% | 100.06% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 153.36% | 51.73% | -157.63% | -338.04% | -35.48% |
| Change in Net Operating Assets | -95.76% | 72.62% | -264.78% | 165.78% | -420.87% |
| Cash from Operations | 441.07% | 24.25% | -72.65% | 22.08% | 16.48% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -2.30% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -99.97% | -40.07% | 709.18% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 45.05% | 51.16% | -108.10% | 577.59% | -111.03% |
| Cash from Financing | 1,141.67% | 50.90% | -105.89% | 120.72% | -68.92% |
| Foreign Exchange rate Adjustments | 130.72% | -299.93% | -14.20% | 186.77% | -154.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 439.03% | 17.15% | -427.35% | 179.73% | -185.59% |